A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy Adults

Inclusion criteria: 1. Body mass index (BMI) greater than or equal to (\>=) 18.0 and less than or equal to (\<=) 32.0 kilograms per square meter (kg/m\^2) at the screening visit. 2. Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs, and Electrocardiograms (ECGs) as outlined in the protocol. Part 1 Only: 3. Healthy, adult, female, aged 18 to 65 years, inclusive, at the screening visit. Parts 2-4 Only: 4. Healthy, adult, male or female, aged 18 to 55 years, inclusive, at the screening visit. Exclusion criteria: 1. Positive urine drug or alcohol results at the screening visit or at check-in. 2. Unable to refrain from or anticipates the use of: * Any drugs, including prescription and non-prescription medications, herbal remedies, or vitamin supplements and other drugs outlined in protocol. * Any drugs known to be inducers of Cytochrome P450 3A4 (CYP3A4) and/or P-gp, including St. John's Wort, for 28 days prior to the first dosing. 3. Has been on a diet incompatible with the on-trial diet, in the opinion of the investigator or designee, within the 30 days prior to first dosing and throughout the trial. 4. Has made a donation of blood or had significant blood loss within 56 days prior to first dosing. 5. Has made a plasma donation within 7 days prior to first dosing. 6. Participated in another clinical trial within 30 days prior to first dosing. The 30-day window will be derived from the date of the last dosing in the previous trial to Day 1 of Period 1 of the current trial. 7. Has herpes infections. 8. Positive results for non-herpetic viral diseases at the screening visit. 9. Positive results for tuberculosis (TB) at the screening visit. Part 1: 10. Unable to refrain from or anticipates the use of: * Any drugs known to increase or decrease levels of sex hormone-binding globulin (SHBG), including any oral, topical, or intravaginal hormone-containing product, within 12 weeks prior to the first dosing. * Any injectable or implantable hormone-containing product within 1 year prior to the first dosing. Part 2 Only: 11. Hemoglobin A1c (HbA1c) greater than (\>) ULN (5.7 percentage \[%\]) and deemed clinically significant by the investigator or designee at the screening visit. Part 3 Only: 12. Has or is at risk for major cardiac events or dysfunction. Part 4 Only: 13. Had diarrhea or vomiting within 48 hours prior to check-in.